Adalimumab biosimilar - LG Life Sciences

Drug Profile

Adalimumab biosimilar - LG Life Sciences

Alternative Names: LBAL

Latest Information Update: 17 May 2016

Price : $50

At a glance

  • Originator LG Life Sciences
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Rheumatoid arthritis

Most Recent Events

  • 18 Apr 2016 LG Life Sciences and Mochida Pharmaceutical plan a phase III trial for Rheumatoid arthritis (Adjunctive treatment, Treatment-experienced) in South Korea and Japan (SC) (NCT02746380)
  • 01 Apr 2016 Phase-III clinical trials in Rheumatoid arthritis (Adjunctive treatment) in Japan (SC) (NCT02746380)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top